## Most Common Tumor Marker in Hepatocellular Carcinoma **Key Point:** Alpha-fetoprotein (AFP) is the most commonly elevated tumor marker in hepatocellular carcinoma (HCC), present in 60–70% of HCC cases, particularly in advanced disease. ### Clinical Significance of AFP in HCC **High-Yield:** AFP levels correlate with tumor burden and prognosis: - AFP > 400 ng/mL: highly suggestive of HCC in a cirrhotic patient - AFP 200–400 ng/mL: intermediate risk; requires imaging confirmation - AFP < 200 ng/mL: does not exclude HCC; imaging remains the gold standard ### Role in Surveillance and Diagnosis **Clinical Pearl:** In patients with cirrhosis, AFP screening every 3–6 months combined with ultrasound is recommended for early HCC detection. AFP alone is insufficient for diagnosis due to: - Low sensitivity in early HCC (40–50%) - Non-specific elevation in chronic hepatitis and cirrhosis - Benign causes: pregnancy, germ cell tumors, hepatitis flares ### Comparison with Other Markers in HCC | Marker | Sensitivity in HCC | Specificity | Primary Use | |--------|-------------------|-------------|-------------| | **AFP** | 60–70% (advanced) | 80–90% (>400 ng/mL) | Screening, prognosis | | CEA | 10–20% | Low | Colorectal/gastric CA | | CA 19-9 | 15–30% | Low | Cholangiocarcinoma | | PIVKA-II | 40–50% | Higher than AFP | Emerging marker | **Mnemonic:** **HCC-AFP**: **H**epatocellular carcinoma uses **A**lpha-**F**etoprotein as the **P**rimary marker; **C**arcinoembryonic antigen is for **C**olorectal disease. ### Why AFP is Preferred Over Other Markers 1. **Historical precedent:** First tumor marker used clinically (1960s) 2. **Prognostic value:** Elevated AFP predicts worse survival and higher recurrence risk 3. **Guideline recommendation:** AASLD, EASL, and NCCN all recommend AFP in HCC surveillance 4. **Cost-effective:** Inexpensive, widely available, rapid turnaround [cite:Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.